COMMENTTeva and MedinCell looking to enter increasingly competitive LAI schizophrenia marketToralgen’s insulin-delivering nano-particle therapy accepted into FDA’s Emerging Technology ProgramMarket insightJapan's lack of injectable anti-HIV treatments A lack of injectable anti-HIV therapies in the Japanese market limits treatment options for dysphagic patientscommentPreventing thrombosis in Covid-19 patientsinsightCoronavirus variant causing concern in South AfricaToralgen’s insulin-delivering nano-particle therapy accepted into the FDA’s Emerging Technology ProgramTeva and MedinCell looking to enter increasingly competitive LAI schizophrenia market02/23/2024 23:27:44
Toralgen’s insulin-delivering nano-particle therapy accepted into the FDA’s Emerging Technology Program
Teva and MedinCell looking to enter increasingly competitive LAI schizophrenia market